What's breaking now, across thousands of outlets.
The deal with the buzzy Flagship Pioneering-backed startup makes J&J the latest large drugmaker to bet that the technology might be able to treat autoimmune conditions.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
Learn how to balance screen time and offline life, improve mental well-being, reduce digital stress, and build healthier daily habits. (And stay sane.)
A new study finds that ocean temperatures thousands of kilometers away shape soil moisture in Malawi, offering a potential tool for forecasting malaria outbreaks months in advance.
Pfizer reports Phase 3 wins for Litfulo: The drug succeeded in two trials for active and stable nonsegmental vitiligo, an autoimmune condition that causes skin to progressively lose its color. One ...
The Trump administration’s nominee to be the next CDC director has won the support of a key Senate committee, sending her nomination to the full Senate for likely confirmation.
Regulators say the telehealth company illegally shared patients’ health data with advertisers and misled its customers. Hims & Hers hit back, calling the claims “baseless.”
“What a relief, a breath of fresh air, to be reminded what the barest, sloppiest propaganda can look like.”
